Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers [Phase 1]
A first-in-human Phase 1a/1b study of CT-202, a nectin-4 directed bispecific antibody, in patients with recurring triple-negative breast can…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2, Phase 3]
Clinical Trial Update for BEBT-209 in combination with chemotherapy for Locally Advanced Triple-negative Breast Cancer or Metastatic Triple-…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer [Phase 2]
A Phase II trial update for Trilaciclib in combination with pembrolizumab, gemcitabine, and carboplatin in metastatic triple-negative breast…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer [EARLY_Phase 1]
An early-phase clinical trial from MD Anderson uses DCE-MRI and molecular breast imaging to assess chemotherapy response in patients with tr…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors [Phase 1]
NiKang Therapeutics is conducting a Phase 1 study of NKT3964 in adults with advanced or metastatic solid tumors, and the trial is currently …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [Phase 1]
Phase 1 trial evaluating [225Ac]Ac-AKY-1189 for solid tumors is currently recruiting, including urothelial carcinoma of the bladder and trip…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: FMD and Neoadjuvant Chemo-immunotherapy in TNBC [Phase 2]
Phase 2 clinical trial evaluating FMD in combination with neoadjuvant chemo-immunotherapy for triple-negative breast cancer; currently recru…
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors [Phase 1]
Phase I study update for the radiopharmaceutical [177Lu]Lu-DFC413 in patients with various solid tumors, currently recruiting.
-
CLINICAL_TRIALS other · 2026-04-21Clinical Trial Update: ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer [Phase 3]
A Phase 3 clinical trial update announcing recruitment for pumitamig in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) [Phase 3]
Phase 3 clinical trial update describing Sacituzumab tirumotecan as a monotherapy and in combination with pembrolizumab for triple-negative …
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation [Phase 2]
Phase 2 clinical trial update for ASTRAEA investigating a combination of myeloid inhibition and radiation in metastatic triple-negative brea…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study of Tetrathiomolybdate (TM) Plus Capecitabine [Phase 1, Phase 2]
Ongoing Phase 1/2 study evaluating tetrathiomolybdate (TM) plus capecitabine for triple-negative breast cancer with residual disease; curren…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation [Phase 2]
Phase 2 study evaluating a combination of myeloid inhibition and radiation to enhance immunotherapy responses in triple-negative breast canc…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Phase 1 of CTX-8371 in Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating CTX-8371 in patients with advanced malignancies, including Non-Small Cell Lung Cancer and Triple-Negative …
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) [Phase 3]
Phase 3 study comparing BL-B01D1 to physician's choice chemotherapy in unresectable locally advanced or metastatic triple-negative breast ca…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 trial update evaluating PF-08032562 in people with advanced or metastatic solid tumors, including breast cancer and colorectal cance…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy [NA]
An open-label prospective study to evaluate the efficacy and safety of pegfilgrastim in patients with triple-negative breast cancer receivin…
-
CLINICAL_TRIALS other · 2026-04-20Clinical Trial Update: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors [Phase 1]
Clinical trial update for PF-08046054/SGN-PDL1V in advanced solid tumors shows a Phase 1 study is currently recruiting across multiple indic…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating high-dose radiation therapy with pembrolizumab and chemotherapy in PD-L1–positive metastatic triple-negative breast…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial is evaluating adding an individualized cancer vaccine to durvalumab, tremelimumab, and chemotherapy in patients with metasta…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) [Phase 3]
A Phase 3 study of sacituzumab govitecan (Sac-TMT, MK-2870) for breast cancer is currently recruiting. The trial includes patients with trip…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Study of LY4175408 in Participants With Advanced Cancer [Phase 1]
A Phase 1 clinical trial evaluating LY4175408 in participants with advanced cancers, including non-small cell lung cancer, small cell lung c…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This is an open-label, multicenter expanded access protocol to provide leronlimab to patients with locally advanced or metastatic triple-neg…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer [Phase 1]
Phase 1 clinical trial update for CF33-hNIS-antiPDL1 in metastatic triple-negative breast cancer shows the study is currently ACTIVE_NOT_REC…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer [Phase 2]
This Phase 2 trial assesses avelumab in combination with binimetinib, sacituzumab govitecan, or liposomal doxorubicin in patients with stage…